ASPI, ASP Isotopes Inc

"Loading Stock Price & Valuation Data ..."

Agentic AI (Pro) Picks for ASPI

History

Run pick agents

SI subscription required
Agentic AI (pro) subscription required



Big Events:

See Big Events by Subscribing to Premium



Short Seller Reports & Red Flags:

See Short Seller Reports by Subscribing to Premium

News: Subscribe to get AI-powered News Summary

Loading news...




Unlock Ask ASPI by Subscribing to iPick.ai Premium!



Stock Chart



See Competitors by Subscribing to Premium

Competitors:


Latest YouTube Video:

See YouTube Video by Subscribing to Premium

Unlock YouTube Video by Subscribing to iPick.ai Premium!



Billionaire Connection

See Billionaire Connection by Subscribing to Premium

Business Profile

Address: 2200 Ross Avenue, Suite 4575E, Dallas, TX, United States, 75201

Employees: 271

Business Summary

ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.

Leadership and Board

Mr. Paul Elliot Mann C.F.A.

Executive Chairman & CEO

Ms. Heather Kiessling

Chief Financial Officer

Mr. Robert Ainscow

Chief Operating Officer

Mr. Nicholas Michael Mitchell

Co-Chief Operating Officer

Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D.

Chief Technology Officer

Ms. Shveta Vilas Dighe

Head of Investor Relations

Mr. Donald George Ainscow

EVP, General Counsel & Secretary

Mr. Stefano Marani

President of Electronics & Space

Dr. Gerdus Kemp M.D., Ph.D.

Medical Director & CEO of Pet Labs